Clinical Trial Update: Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the combination of antithymocyte globulin and sirolimus in patients with relapsed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasms

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)
• Sirolimus (Sirolimus)

Snippet

Sponsor: University of Rochester | Conditions: Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Status: COMPLETED